RU58841 combined with finasteride or dutasteride is more effective than RU58841 alone for hair loss. Users suggest combining these with minoxidil and microneedling for better results.
The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.
A humorous discussion about hair regrowth using finasteride, with jokes about telekinesis and tiny ants. The conversation is satirical, with users making light of hair loss treatments.
PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.
PP405 shows promising results for hair growth, potentially outperforming finasteride without side effects like erectile dysfunction. Users discuss using treatments like minoxidil, pyrilutamide, nizoral, and alfatradiol while waiting for PP405's availability.
The conversation discusses buying RU58841 directly from a Chinese supplier for cost savings. It mentions that companies like Anageninc and Actifolic do the same.
RU58841 users report mixed results, with some experiencing no benefits and others noting regrowth but potential side effects. Many prefer finasteride and minoxidil due to better-studied safety profiles.
A 25-year-old is starting finasteride to address hair loss, having previously used minoxidil and other treatments. Users discuss experiences with finasteride, including initial shedding and side effects, while offering advice and support.
A 19-year-old experienced significantly low testosterone levels after one month of taking finasteride. Suggestions included checking test units, retesting, and exploring other potential causes.
Oleic acid and microneedling are being explored for hair regrowth, but results are mixed. Addressing DHT and fibrosis is crucial, with treatments like finasteride, minoxidil, and scalp massage also discussed.
Finasteride is key for hair regrowth, supported by oral/topical minoxidil, Folexin, Nizoral/Head & Shoulders, and vitamin D. No side effects experienced; early intervention and patience are crucial.
PP405 is expected to be more expensive than finasteride and minoxidil initially due to patent protection, but not as costly as life-saving medications like Ozempic. The price may decrease after the patent expires, but initially, it might be around $100 per month, making it potentially unaffordable for many.
Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.
Sulforaphane shows potential for hair regrowth, with users reporting reduced shedding and regrowth. Some users combine it with Minoxidil and finasteride for better results.
The conversation discusses whether Pyrilutamide from Koshine is different from Anageninc and if it's effective for hair loss. It also questions if sticking to RU58841 would be better.
Vitamin E and K deficiencies due to exocrine pancreatic insufficiency may affect hair growth. A scalp biopsy is recommended to check for autoimmune-related hair loss.
PP405 is progressing rapidly through trials, with mixed opinions on its potential effectiveness. Current treatments like minoxidil and finasteride are still widely discussed, with some users reporting positive results from new formulations.
The conversation is about comparing the effectiveness of 5% RU58841 and 0.5% pyrilutamide for hair loss treatment. The user is asking if the higher concentration of RU58841 makes it stronger than the lower dose of pyrilutamide.
Koshine is considered less effective than finasteride, dutasteride, and RU58841 for hair loss treatment. One user reported positive results with Koshine, but others found it ineffective.
RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.
The conversation is about the lack of discussion on Low-level laser light therapy (LLLT) laser caps for hair loss. One user questions their effectiveness, and another asserts they don't work.
A user has been taking finasteride, using a derma-roller, LLLT, and argan oil, but experienced significant hair loss at the one-year mark. They are concerned if this is a normal shedding phase or something to worry about.
A user is considering using both oral and topical finasteride for hair loss, despite having elevated liver enzymes. They currently use a topical spray with finasteride and minoxidil and are seeking advice on whether using both forms is advisable.
User had a 5000-hair FUT procedure in South Korea in 2014 and is satisfied with results. Uses Minoxidil, dermarolling, and Toppik hair fibers for crown area, and considering Finasteride.
PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.
Combining microneedling with Low Level Laser Therapy (LLLT) for hair growth, with discussions on device legitimacy and effectiveness. Alternatives like PEMF and the use of oral and topical treatments such as dutasteride, minoxidil, and finasteride are also considered.
Topical finasteride in a liposomal formulation reduces systemic absorption compared to ethanol solutions. The user is seeking sources for such products, noting that popular options like morr-f are not liposomal.
The user plans to improve hair density using Koshine, Avodart (1.5-2.5mg daily), and 5mg OM daily. They previously used finasteride, minoxidil, dutasteride, and fluridil with some improvement.
PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.